Precipio, Inc.
Business
Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly hematologic malignancies, through an integrated model combining clinical laboratory services with proprietary diagnostic product development. The company operates two complementary divisions: a Pathology Services Division providing specialized cancer diagnostic testing to physicians and hospitals, and a Products Division developing and commercializing proprietary diagnostic assays for use by other laboratories. Precipio serves the U.S. oncology diagnostic market from its New Haven, Connecticut clinical laboratory, which also functions as a self-funded research and development platform.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue, net of contractual allowances and adjustments | 24 | 19 | 15 | 10 | 9 | |
| Adjustment for allowance for credit losses | −197,000 | −44,000 | −218,000 | −408,000 | 152,000 | |
| Net sales | 24 | 19 | 15 | 9 | 9 | |
| Total cost of sales | 13 | 11 | 9 | 7 | 6 | |
| Gross profit | 11 | 8 | 6 | 3 | 2 | |
| Operating expenses | 12 | 12 | 14 | 15 | 12 | |
| OPERATING LOSS | −1 | −4 | −8 | −13 | −10 | |
| Interest expense, net | −73,000 | −74,000 | — | — | — | |
| Gain on settlement of liability | 143,000 | — | — | — | — | |
| Employee Retention Credit | 789,000 | — | — | — | — | |
| Other expense | −20,000 | — | — | — | — | |
| Total other income (expense) | 839,000 | −74,000 | — | — | — | |
| LOSS BEFORE INCOME TAXES | −363,000 | −4 | −6 | −12 | −9 | |
| INCOME TAX EXPENSE | 0 | 0 | 0 | 0 | 0 | |
| NET LOSS | −363,000 | −4 | — | — | — | |
| BASIC LOSS PER COMMON SHARE | −0.23 | −2.93 | −4.51 | −10.73 | −0.4 | |
| BASIC WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING | 2 | 1 | 1 | 1 | 21 | |
| DILUTED LOSS PER COMMON SHARE | −0.23 | −2.93 | −4.51 | −10.73 | −0.4 | |
| DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING | 2 | 1 | 1 | 1 | 21 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-04-30 |
|---|---|---|---|---|---|---|
| Cash | 3 | 1 | 2 | 3 | — | |
| Accounts receivable (net of allowance for credit losses of $1,045 and $995, respectively) | 2 | 799,000 | 1 | 1 | — | |
| Inventories | 935,000 | 724,000 | 384,000 | 708,000 | — | |
| Other current assets | 500,000 | 500,000 | 500,000 | 500,000 | — | |
| Total current assets | 6 | 3 | 4 | 6 | — | |
| PROPERTY AND EQUIPMENT, NET | 729,000 | 719,000 | 739,000 | 877,000 | — | |
| Finance lease right-of-use assets, net | 998,000 | 517,000 | 174,000 | 257,000 | — | |
| Operating lease right-of-use assets, net | 3 | 395,000 | 612,000 | 763,000 | 100,000 | |
| Intangibles, net | 11 | 12 | 13 | 14 | — | |
| Other assets | 67,000 | 45,000 | 76,000 | 129,000 | — | |
| Total assets | 21 | 17 | 18 | 22 | — | |
| Current maturities of long-term debt, less debt issuance costs | 30,000 | 297,000 | 235,000 | 255,000 | — | |
| Current maturities of finance lease liabilities | 209,000 | 124,000 | 132,000 | 162,000 | — | |
| Current maturities of operating lease liabilities | 410,000 | 201,000 | 218,000 | 199,000 | — | |
| Accounts payable | 1 | 618,000 | 622,000 | 2 | — | |
| Accrued expenses | 2 | 3 | 2 | 2 | — | |
| Deferred revenue | 300,000 | 200,000 | 100,000 | 100,000 | — | |
| Total current liabilities | 4 | 4 | 3 | 4 | — | |
| Long-term debt, less current maturities and debt issuance costs | 47,000 | 77,000 | 106,000 | 134,000 | — | |
| Finance lease liabilities, less current maturities | 751,000 | 348,000 | 18,000 | 68,000 | — | |
| Operating lease liabilities, less current maturities | 2 | 206,000 | 407,000 | 574,000 | — | |
| Total liabilities | 7 | 5 | 4 | 5 | — | |
| COMMITMENTS AND CONTINGENCIES (Note 8) | — | — | — | — | — | |
| Preferred stock - $0.01 par value, 15,000,000 shares authorized at December 31, 2025 and December 31, 2024, 47 shares issued and outstanding at December 31, 2025 and December 31, 2024, liquidation preference of $135 at December 31, 2025 | — | — | — | — | — | |
| Common stock, $0.01 par value, 150,000,000 shares authorized at December 31, 2025 and December 31, 2024, 1,780,899 and 1,493,639 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 18,000 | 15,000 | 14,000 | 11,000 | — | |
| Additional paid-in capital | 117 | 115 | 113 | 109 | — | |
| Accumulated deficit | −103 | −102 | −98 | −92 | — | |
| Total stockholders' equity | 15 | 12 | 14 | 16 | — | |
| Total liabilities and stockholders' equity | 21 | 17 | 18 | 22 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 1 | 1 | 1 | 1 | 1 | |
| Amortization of operating lease right-of-use asset | 319,000 | 217,000 | 209,000 | 187,000 | 219,000 | |
| Amortization of finance lease right-of-use asset | 188,000 | 97,000 | 83,000 | 114,000 | 94,000 | |
| Amortization of deferred financing costs, debt discounts and debt premiums | 3,000 | 3,000 | 3,000 | 4,000 | 3,000 | |
| Stock-based compensation | 1 | 1 | 2 | 4 | 2 | |
| Value of stock issued in payment of Board fees and consulting services | 241,000 | 386,000 | 177,000 | — | 150,000 | |
| Provision for credit losses | 177,000 | 64,000 | 218,000 | 406,000 | −150,000 | |
| Derecognition of finance lease right-of-use asset and liability | −4,000 | 2,000 | — | — | — | |
| Derecognition of operating lease right-of-use asset and liability | −38,000 | — | — | — | — | |
| Loss on disposal of asset | 20,000 | — | — | — | — | |
| Accounts receivable | −1 | 438,000 | −483,000 | −745,000 | 327,000 | |
| Inventories | −211,000 | −340,000 | 324,000 | −144,000 | −214,000 | |
| Other assets | 48,000 | 303,000 | 451,000 | 491,000 | −349,000 | |
| Accounts payable | 513,000 | −10,000 | −169,000 | 165,000 | 112,000 | |
| Operating lease liabilities | −241,000 | −218,000 | −206,000 | −182,000 | −225,000 | |
| Deferred revenue | 50,000 | 122,000 | −9,000 | 101,000 | 12,000 | |
| Accrued expenses | −966,000 | 975,000 | 698,000 | −329,000 | −58,000 | |
| Net cash provided by operating activities | 700,000 | 439,000 | −4 | −8 | −7 | |
| Purchase of property and equipment | −326,000 | −223,000 | −126,000 | −277,000 | −682,000 | |
| Net cash used in investing activities | −326,000 | −223,000 | −126,000 | −277,000 | −682,000 | |
| Principal payments on finance lease obligations | −157,000 | −92,000 | −80,000 | −151,000 | −130,000 | |
| Deposits on finance lease right-of-use assets | −20,000 | −28,000 | — | — | — | |
| Issuance of common stock, net of issuance costs | — | 78,000 | 2 | 129,000 | 16 | |
| Proceeds from exercise of warrants | 1 | — | — | 11,000 | 400,000 | |
| Proceeds from exercise of stock options | 119,000 | — | — | — | 3,000 | |
| Proceeds from debt | — | 250,000 | — | — | — | |
| Principal payments on long-term debt | −300,000 | −537,000 | −423,000 | −214,000 | −40,000 | |
| Net cash flows provided by (used in) financing activities | 903,000 | −329,000 | 2 | −225,000 | 16 | |
| NET CHANGE IN CASH | 1 | −113,000 | −2 | −8 | 9 | |
| Cash paid during the period for interest | 100,000 | 85,000 | 42,000 | 45,000 | 34,000 | |
| Purchases of equipment financed through accounts payable | — | 6,000 | 11,000 | 34,000 | 58,000 | |
| Prepaid insurance financed with loan | — | 317,000 | 372,000 | 413,000 | — | |
| Operating lease right-of-use assets obtained in exchange for operating lease obligations | 3 | 0 | 100,000 | 100,000 | 800,000 | |
| Finance lease right-of-use assets obtained in exchange for finance lease obligations | 649,000 | 414,000 | — | 12,000 | 347,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Precipio, Inc.'s CIK number?
Precipio, Inc.'s SEC CIK number is 0001043961 (1043961). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Precipio, Inc.'s SEC filings?
All of Precipio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Precipio, Inc. last report earnings?
Precipio, Inc. (PRPO) most recently filed an earnings 8-K with the SEC on Feb 27, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-021625). This is Precipio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Precipio, Inc.'s most recent earnings 8-K?
Precipio, Inc.'s latest earnings 8-K (Item 2.02) was filed Feb 27, 2026 under accession 0001104659-26-021625. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Precipio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →